Global prevalence of depression and anxiety in patients with hepatocellular carcinoma: Systematic review and meta-analysis

다국어 초록 (Multilingual Abstract)

Background/Aims: Depression and anxiety are associated with poorer outcomes in patients with hepatocellular carcinoma (HCC). However, the prevalence of depression and anxiety in HCC are unclear. We aimed to establish the prevalence of depression and anxiety in patients with HCC.
Methods: MEDLINE and Embase were searched and original articles reporting prevalence of anxiety or depression in patients with HCC were included. A generalized linear mixed model with Clopper-Pearson intervals was used to obtain the pooled prevalence of depression and anxiety in patients with HCC. Risk factors were analyzed via a fractional-logistic regression model.
Results: Seventeen articles involving 64,247 patients with HCC were included. The pooled prevalence of depression and anxiety in patients with HCC was 24.04% (95% confidence interval [CI], 13.99–38.11%) and 22.20% (95% CI, 10.07–42.09%) respectively. Subgroup analysis determined that the prevalence of depression was lowest in studies where depression was diagnosed via clinician-administered scales (16.07%;95% CI, 4.42–44.20%) and highest in self-reported scales (30.03%; 95% CI, 17.19–47.01%). Depression in patients with HCC was lowest in the Americas (16.44%; 95% CI, 6.37–36.27%) and highest in South-East Asia (66.67%; 95% CI, 56.68–75.35%). Alcohol consumption, cirrhosis, and college education significantly increased risk of depression in patients with HCC.
Conclusions: One in four patients with HCC have depression, while one in five have anxiety. Further studies are required to validate these findings, as seen from the wide CIs in certain subgroup analyses. Screening strategies for depression and anxiety should also be developed for patients with HCC.

참고문헌 (Reference)

• 1 Hwa KJ, "psychosocial obstacles in Veterans with hepatocellular carcinoma" 17 : 1124-1129, 2015
• 2 Fletcher J, "What is heterogeneity and is it important?" 334 : 94-96, 2007
• 3 Li L, "Value of quality of life analysis in liver cancer : a clinician’s perspective" 9 : 867-883, 2017
• 4 Wolf E, "Use of hepatocellular carcinoma surveillance in patients with cirrhosis : a systematic review and meta-analysis" 73 : 713-725, 2021
• 5 Darren Jun Hao Tan, "UNOS Down-Staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies" Elsevier BV 2022
• 6 Clopper CJ, "The use of confidence or fiducial limits illustrated in the case of the binomial" 26 : 404-413, 1934
• 7 Steel J, "The role of psychosocial factors in the progression of hepatocellular carcinoma" 62 : 86-94, 2004
• 8 Agarwal P, "The prevalence of psychosocial barriers and their impact on receipt of HCC care in US veterans : role of tumor board model of care" 6 : 1-5, 2021
• 9 Munn Z, "The development of a critical appraisal tool for use in systematic reviews addressing questions of prevalence" 3 : 123-128, 2014
• 10 Strine TW, "The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults" 30 : 127-137, 2008
• 11 Lee KS, "Tenets for the proper conduct and use of meta-analyses : a practical guide for neurosurgeons" 161 : 291-302, 2022
• 12 Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a metaanalysis" 154 : 1706-1718, 2018
• 13 Uddin R, "Suicidal ideation, suicide planning, and suicide attempts among adolescents in 59 low-income and middle-income countries : a population-based study" 3 : 223-233, 2019
• 14 Cheng HH, "Socioeconomic disparities of depressive symptoms and cytokines in hepatocellular carcinoma" 28 : 1624-1632, 2019
• 15 Prescott CA, "Sex-specific genetic influences on the comorbidity of alcoholism and major depression in a population-based sample of US twins" 57 : 803-811, 2000
• 16 Schwarzer G, "Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions" 10 : 476-483, 2019
• 17 Chang CH, "Risk of developing depressive disorders following hepatocellular carcinoma : a nationwide population-based study" 10 : e0135417-, 2015
• 18 Golden J, "Reliability and validity of the hospital anxiety and depression scale and the beck depression inventory(full and fastscreen scales)in detecting depression in persons with hepatitis C" 100 : 265-269, 2007
• 19 Ahmed S, "Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization" 2016 : 6120143-, 2016
• 20 Gandhi S, "Quality of life and hepatocellular carcinoma" 5 : 296-317, 2014
• 21 Palmieri VO, "Psychopathological profile and health-related quality of life(HRQOL)in patients with hepatocellular carcinoma(HCC)and cirrhosis" 15 : 65-72, 2015
• 22 Bianchi G, "Psychological status and depression in patients with liver cirrhosis" 37 : 593-600, 2005
• 23 Temtap S, "Psychological distress and concerns in thai patients with hepatocellular cancer" 2018
• 24 Graf J, "Psychological burden and psycho-oncological interventions for patients with hepatobiliary cancers-a systematic review" 12 : 662777-, 2021
• 25 Ismail Z, "Prevalence of depression in patients with mild cognitive impairment : a systematic review and meta-analysis" 74 : 58-67, 2017
• 26 Krebber AM, "Prevalence of depression in cancer patients : a metaanalysis of diagnostic interviews and self-report instruments" 23 : 121-130, 2014
• 27 Hong JS, "Prevalence of anxiety and depression and their risk factors in Chinese cancer patients" 22 : 453-459, 2014
• 28 Steel JL, "Preliminary results of an individually tailored psychosocial intervention for patients with advanced hepatobiliary carcinoma" 25 : 19-42, 2007
• 29 Low CJ, "Outcomes of left ventricular thrombosis in post-acute myocardial infarction patients stratified by antithrombotic strategies : a metaanalysis with meta-regression" 329 : 36-45, 2021
• 30 Lai SW, "No association between depression and risk of hepatocellular carcinoma in older people in Taiwan" 2013 : 901987-, 2013
• 31 Lange S, "National, regional, and global prevalence of smoking during pregnancy in the general population : a systematic review and meta-analysis" 6 : e769-e776, 2018
• 32 DerSimonian R, "Meta-analysis in clinical trials" 7 : 177-188, 1986
• 33 Tian Y, "Mental profile and related factors in 112inpatients with hepatocarcinoma" 10 : 16-18, 2006
• 34 Koh JH, "Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria : a meta-analysis of 18, 421 patients" 11 : 78-93, 2022
• 35 Jia L, "Investigation of the incidence of pancreatic cancer-related depression and its relationship with the quality of life of patients" 82 : 4-9, 2010
• 36 Rice DR, "Impact of psychiatric illness on survival among patients with hepatocellular carcinoma" 25 : 3242-3243, 2021
• 37 Lee HH, "Impact of preoperative anxiety and depression on quality of life before and after resection of hepatocellular carcinoma" 246 : 361-367, 2019
• 38 Llovet JM, "Hepatocellular carcinoma" 7 : 6-, 2021
• 39 Feldbrügge L, "Health-related quality of life and mental health after surgical treatment of hepatocellular carcinoma in the era of minimal-invasive surgery: resection versus transplantation" 9 : 694-, 2021
• 40 Lim WH, "Global prevalence, risk factors, and outcomes of depression after liver transplant : a systematic review and meta-analysis" 1 : 150-159, 2022
• 41 Sung H, "Global cancer statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185countries" 71 : 209-249, 2021
• 42 Darren Jun Hao Tan, "Global burden of liver cancer in males and females: Changing etiological basis and the growing contribution of NASH" Ovid Technologies (Wolters Kluwer Health) 77 (77): 1150-1163, 2022
• 43 Reveron-Thornton RF, "Global and regional long-term survival following resection for HCC in the recent decade : a meta-analysis of 110studies" 6 : 1813-1826, 2022
• 44 Tufanaru C, "Fixed or random effects meta-analysis? Common methodological issues in systematic reviews of effectiveness" 13 : 196-207, 2015
• 45 Bell A, "Fixed and random effects models : making an informed choice" 53 : 1051-1074, 2019
• 46 Wan X, "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range" 14 : 135-, 2014
• 47 Abureesh M, "Epidemiology of depressive disorders in patients with liver cirrhosis : a population-based study in the United States" 24 : 20m-, 2022
• 48 Graham K, "Does the association between alcohol consumption and depression depend on how they are measured?" 31 : 78-88, 2007
• 49 Lynskey MT, "Differential criterion functioning of alcohol use symptomatology in major depressive disorder?" 38 : 441-449, 2008
• 50 Mikoshiba N, "Depressive symptoms after treatment in hepatocellular carcinoma survivors : prevalence, determinants, and impact on health-related quality of life" 22 : 2347-2353, 2013
• 51 Ho GWK, "Depression literacy and health-seeking attitudes in the Western Pacific region : a mixed-methods study" 53 : 1039-1049, 2018
• 52 Shirazian S, "Depression in chronic kidney disease and end-stage renal disease : similarities and differences in diagnosis, epidemiology, and management" 2 : 94-107, 2016
• 53 Smith HR, "Depression in cancer patients : pathogenesis, implications and treatment(review)" 9 : 1509-1514, 2015
• 54 Mohamed S, "Depression and psychosocial correlates of liver transplant candidates : a systematic review" 6 : 447-453, 2014
• 55 Pitman A, "Depression and anxiety in patients with cancer" 361 : k1415-, 2018
• 56 Sykes DB, "Complete Responses in the TEMPI syndrome after treatment with daratumumab" 378 : 2240-2242, 2018
• 57 Chu TL, "Comparison of differences and determinants between presence and absence of sleep disturbance in hepatocellular carcinoma patients" 34 : 354-360, 2011
• 58 Huang DQ, "Comparative efficacy of an optimal exam between ultrasound versus abbreviated MRI for HCC screening in NAFLD cirrhosis : a prospective study" 55 : 820-827, 2022
• 59 Tan DJH, "Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma : a systematic review and meta-analysis" 23 : 521-530, 2022
• 60 Huang DQ, "Changing global epidemiology of liver cancer from 2010 to 2019 : NASH is the fastest growing cause of liver cancer" 34 : 969-977, 2022
• 61 Li F, "Assessing the accuracy of diagnostic tests" 30 : 207-212, 2018
• 62 Lee KT, "Anxiety and depression are associated with long-term outcomes of hepatocellular carcinoma : a nationwide study of a cohort from Taiwan" 19 : 431-439, 2018
• 63 Linden W, "Anxiety and depression after cancer diagnosis : prevalence rates by cancer type, gender, and age" 141 : 343-351, 2012
• 64 Paro A, "ASO author reflections : association of depression with in-patient and post-discharge disposition and expenditures among medicare beneficiaries undergoing resection for cancer" 28 : 6535-6536, 2021
• 65 Wee IJY, "A systematic review and meta-analysis on the quality of life after hepatic resection" 22 : 177-186, 2020
• 66 Wang J, "A randomized clinical trial of comprehensive education and care program compared to basic care for reducing anxiety and depression and improving quality of life and survival in patients with hepatocellular carcinoma who underwent surgery" 98 : e17552-, 2019
• 67 Jia Y, "A nomogram for predicting depression in patients with hepatocellular carcinoma : an observational cross-sectional study" 23 : 273-280, 2019
• 68 Pedersen CB, "A comprehensive nationwide study of the incidence rate and lifetime risk for treated mental disorders" 71 : 573-581, 2014